Dalimune 50 mg FC tablets
PDF Leaflet Revision Date: 20 February 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV in adults and adolescents over 18 years.
Dosage (summary)
50 mg once daily; 50 mg twice daily if co-administered with certain drugs.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Risk of neural tube defects; avoid breastfeeding.
Key Drug Interactions
- Dofetilide
- Pilsicainide
- Metformin
- Efavirenz
- Nevirapine
- Rifampicin
Contraindications
- Hypersensitivity to dolutegravir
- Moderate/severe hepatic impairment
Common side effects
- Insomnia
- Dizziness
- Nausea
- Rash
- Fatigue
Counselling Points
- Take with or without food
- Monitor for signs of hypersensitivity
- Regular viral load and CD4 count checks
Serious warnings
- Hypersensitivity reactions
- Immune Reconstitution Inflammatory Syndrome
- Osteonecrosis
Important Disclaimer
The Dalimune 50 mg FC tablets professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
